News
ZNTL
1.360
0.00%
0.000
Weekly Report: what happened at ZNTL last week (1109-1113)?
Weekly Report · 6d ago
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Olema Pharmaceuticals (OLMA) and Zentalis Pharmaceuticals (ZNTL)
TipRanks · 11/11 10:40
Zentalis upgraded to Outperform from Neutral at Wedbush
TipRanks · 11/10 16:59
Wedbush upgrades Zentalis to Outperform with DENALI in view
TipRanks · 11/10 16:52
Wedbush Upgrades Zentalis Pharmaceuticals to Outperform, Raises Price Target to $6
Benzinga · 11/10 15:13
Zentalis Pharmaceuticals Price Target Raised to $6.00/Share From $5.00 by Wedbush
Dow Jones · 11/10 14:56
Zentalis Pharmaceuticals Raised to Outperform From Neutral by Wedbush
Dow Jones · 11/10 14:56
Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals (ZNTL)
TipRanks · 11/10 13:16
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
NASDAQ · 11/10 01:01
Zentalis Pharmaceuticals GAAP EPS of -$0.34
Seeking Alpha · 11/09 22:21
Zentalis Reports Third-Quarter 2026 Results and Business Updates
TipRanks · 11/09 22:19
Press Release: Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
Dow Jones · 11/09 21:05
Press Release: Zentalis Pharmaceuticals Reports -3-
Dow Jones · 11/09 21:05
Weekly Report: what happened at ZNTL last week (1102-1106)?
Weekly Report · 11/09 10:00
U.S. Earnings Preview: After Market Close Nov. 6
Dow Jones · 11/06 20:31
Weekly Report: what happened at ZNTL last week (1026-1030)?
Weekly Report · 11/02 10:00
Weekly Report: what happened at ZNTL last week (1019-1023)?
Weekly Report · 10/26 10:00
Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (ZNTL), Bioline RX Ltd Sponsored ADR (BLRX) and Evaxion Biotech (EVAX)
TipRanks · 10/23 17:30
Zentalis announces median OS data from DENALI Part 1b study
TipRanks · 10/23 14:30
Zentalis Pharmaceuticals Presents Data From Its Interim Analysis Of DENALI Part 1b Trial At ESMO Congress 2026
Benzinga · 10/23 14:17
More
Webull provides a variety of real-time ZNTL stock news. You can receive the latest news about Zentalis Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.